ARD-1676

Cat. No.: HY-156111

CAS No.: 2632305-36-1

Molecular Formula: $C_{44}H_{46}ClN_7O_5$

Molecular Weight: 788.33

Target: PROTACs; Androgen Receptor

Pathway: PROTAC; Vitamin D Related/Nuclear Receptor

Storage: 4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (126.85 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.2685 mL	6.3425 mL	12.6850 mL
	5 mM	0.2537 mL	1.2685 mL	2.5370 mL
	10 mM	0.1269 mL	0.6343 mL	1.2685 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

ARD-1676 is an orally available androgen receptor (AR) PROTAC degrader, consisting of AR ligand and cereblon ligand. ARD-1676 has AR-degrading activity in vitro and in vivo and inhibits VCaP tumor growth in mouse xenograft tumor models[1].

In Vitro

The DC50 values of ARD-1676 for AR degradation in AR+ VCaP and LNCaP cell lines are 0.1 and 1.1 nM, respectively, and the IC_{50} values in VCaP and LNCaP cell lines are 11.5 and 2.8 nM respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The oral bioavailability of ARD-1676 was 67%, 44%, 31%, and 99% in mice, rats, dogs, and monkeys, respectively. ARD-1676 effectively reduces AR protein levels in mouse VCaP tumor tissues and inhibits tumor growth in VCaP mouse xenograft tumor models[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Xiang W, et al. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer. J Med Chem. 2023 Sep 8..

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA